Pharmacology and clinical efficacy of bisphosphonates

James R. Berenson, Allan Lipton

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Tumor-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Osteoclasts can be activated directly by products produced by tumors or indirectly through other nonmalignant cells. By reducing osteoclastic activity, bisphosphonates inhibit bone resorption. Because these agents were shown to be effective in treating other diseases associated with increased bone resorption, including cancer-related hypercalcemia and Paget's disease of bone, studies were initiated to explore the use of bisphosphonates in patients with osteolytic bone metastases.

Original languageEnglish (US)
Pages (from-to)566-571
Number of pages6
JournalCurrent Opinion in Oncology
Volume10
Issue number6
DOIs
StatePublished - Jan 1 1998

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Pharmacology and clinical efficacy of bisphosphonates'. Together they form a unique fingerprint.

Cite this